title: Advances in human proteomics at high scale with the SOMAscan proteomics platform.
abstract: In 1997, while still working at NeXstar Pharmaceuticals, several of us made a proteomic bet. We thought then, and continue to think, that proteomics offers a chance to identify disease-specific biomarkers and improve healthcare. However, interrogating proteins turned out to be a much harder problem than interrogating nucleic acids. Consequently, the 'omics' revolution has been fueled largely by genomics. High-scale proteomics promises to transform medicine with personalized diagnostics, prevention, and treatment. We have now reached into the human proteome to quantify more than 1000 proteins in any human matrix - serum, plasma, CSF, BAL, and also tissue extracts - with our new SOMAmer-based proteomics platform. The surprising and pleasant news is that we have made unbiased protein biomarker discovery a routine and fast exercise. The downstream implications of the platform are substantial.
authors.affiliation: SomaLogic, 2945 Wilderness Place, Boulder, CO 80301, USA.
authors.forename: Larry
authors.initials: L
authors.lastname: Gold
authors.forename: Jeffrey J
authors.initials: JJ
authors.lastname: Walker
authors.forename: Sheri K
authors.initials: SK
authors.lastname: Wilcox
authors.forename: Stephen
authors.initials: S
authors.lastname: Williams
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D004247:DNA / Q000378:metabolism*; D006801:Humans; D011506:Proteins / Q000378:metabolism; D040901:Proteomics / Q000295:instrumentation* / Q000379:methods / Q000639:trends*
chemical_list: D015415:Biomarkers; D011506:Proteins; D004247:DNA